Viewing Study NCT03613532

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:58 PM
Ignite Modification Date: 2026-01-09 @ 10:50 PM
Study NCT ID: NCT03613532
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2018-07-26
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Sponsor: Jacqueline Garcia, MD
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia (AML) View
None Myelodysplastic Syndrome (MDS) View
None Chronic Myelomonocytic Leukemia (CMML) View
None MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable) View
None Hematopoietic Stem Cell Transplant View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myeloid Leukemia (AML) View
None Myelodysplastic Syndrome (MDS) View
None Chronic Myelomonocytic Leukemia (CMML) View
None MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) View
None Hematopoietic Stem Cell Transplant View